Praxis precision medicines announces positive topline results from the embold study in scn2a and 8a developmental epilepsies, highlighting the disease-modifying potential of relutrigine

Placebo-adjusted monthly motor seizure reduction of 46% during double-blind period over 30% of patients achieved seizure freedom status while on relutrigine meaningful gains observed in alertness, communication and seizure severity 75% reduction in median seizure rate seen for patients in the long-term extension registrational phase of the embold study for scn2a and 8a initiated boston, mass., sept. 03, 2024 (globe newswire) -- praxis precision medicines , inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today shared positive topline results for its phase 2, proof of concept study evaluating relutrigine in scn2a and scn8a developmental and epileptic encephalopathy (dee) patients.
PRAX Ratings Summary
PRAX Quant Ranking